^
    Back
    Association details:
    Biomarker:NID1 expression
    Cancer:Glioma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Aging (Albany NY)
    Title:

    Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients

    Published date:
    03/18/2021
    Excerpt:
    These findings demonstrate that NID1 expression in glioma tissues is associated with overall survival of low-grade glioma patients and temozolomide sensitivity. NID1 is thus a potential prognostic biomarker and therapeutic target in low-grade glioma patients.
    DOI:
    10.18632/aging.202789